Αναζήτηση Δραστικών

SIMVASTATIN

Εμπορικές Ονομασίες

  • STAZOR
    Μορφές: F.C.TAB
  • ZOCOR
    Μορφές: F.C.TAB
  • STATINAL
    Μορφές: C.TAB
    Μορφές: F.C.TAB
  • PRELON
    Μορφές: F.C.TAB
  • PLACOL
    Μορφές: F.C.TAB
  • LEPUR
    Μορφές: F.C.TAB
  • GLIPAL
    Μορφές: F.C.TAB
  • RAPTOR
    Μορφές: F.C.TAB
  • SIMVALID
    Μορφές:
    Μορφές: F.C.TAB
  • VASSOR
    Μορφές: F.C.TAB
  • DRUGBANK - Simvastatin
  • indication:

    For the treatment of hypercholesterolemia.

  • pharmacology:

  • mechanism:

    The 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.

  • toxicity:

  • absorprion:

    Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.

  • halflife:

    3 hours

  • roouteelimination:

    Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.

  • volumedistribution:

  • clearance: